Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 ...
VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, ...
VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined progress within its pipeline ...
Xenon (NASDAQ:XENE) Pharmaceuticals Inc (NASDAQ:XENE), a biopharmaceutical company focused on developing innovative therapeutics for neurological disorders, is making significant strides in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback